These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 29611049)

  • 1. Pembrolizumab for primary malignant melanoma of the central nervous system.
    El Habnouni C; Bléchet C; Bens G
    J Neurooncol; 2018 Aug; 139(1):225-227. PubMed ID: 29611049
    [No Abstract]   [Full Text] [Related]  

  • 2. Pembrolizumab for Recurrent Conjunctival Melanoma.
    Kini A; Fu R; Compton C; Miller DM; Ramasubramanian A
    JAMA Ophthalmol; 2017 Aug; 135(8):891-892. PubMed ID: 28715523
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and Toxicity of Pembrolizumab in Pediatric Metastatic Recurrent Melanoma.
    Marjanska A; Galazka P; Marjanski M; Wysocki M; Styczynski J
    Anticancer Res; 2019 Jul; 39(7):3945-3947. PubMed ID: 31262925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete response to pembrolizumab after initial progress in a patient with metastatic uveal melanoma.
    Stauner CT; Drexler K; Berneburg M; Haferkamp S
    J Dtsch Dermatol Ges; 2018 Nov; 16(11):1376-1378. PubMed ID: 30299577
    [No Abstract]   [Full Text] [Related]  

  • 5. Pembrolizumab (Keytruda°) and metastatic or inoperable melanoma.
    Prescrire Int; 2017 May; 26(182):118-119. PubMed ID: 30730667
    [No Abstract]   [Full Text] [Related]  

  • 6. Focal regression of a primary melanoma, fading lentigines and poliosis in metastatic melanoma treated with anti-PD-1.
    Thomas S; Laino A; Sturm R; Nufer K; Lambie D; Shepherd B; Atkinson V; Adams L; Soyer HP; Schaider H
    J Eur Acad Dermatol Venereol; 2018 May; 32(5):e176-e177. PubMed ID: 29114959
    [No Abstract]   [Full Text] [Related]  

  • 7. Killing two birds with one stone: response to pembrolizumab in a patient with metastatic melanoma and B-cell chronic lymphocytic leukaemia.
    Arenbergerova M; Fialova A; Arenberger P; Gkalpakiotis S; Jirasek T; Srp A; Novotna A; Frankova H
    J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):e72-e74. PubMed ID: 28833722
    [No Abstract]   [Full Text] [Related]  

  • 8. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
    Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
    Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
    Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
    Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
    [No Abstract]   [Full Text] [Related]  

  • 10. Antiphospholipid Syndrome Following Pembrolizumab Treatment of Stage IIIB Unresectable Melanoma.
    Sanchez A; Montaudie H; Bory P; Belgodere X; Passeron T; Lacour JP; Picard A
    JAMA Dermatol; 2018 Nov; 154(11):1354-1356. PubMed ID: 30326507
    [No Abstract]   [Full Text] [Related]  

  • 11. The use of pembrolizumab for the treatment of metastatic uveal melanoma.
    Kottschade LA; McWilliams RR; Markovic SN; Block MS; Villasboas Bisneto J; Pham AQ; Esplin BL; Dronca RS
    Melanoma Res; 2016 Jun; 26(3):300-3. PubMed ID: 26848796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment.
    Gulati N; Carvajal RD; Postow MA; Wolchok JD; Krueger JG
    Exp Dermatol; 2016 Jul; 25(7):553-4. PubMed ID: 27061281
    [No Abstract]   [Full Text] [Related]  

  • 13. Vitiligo Repigmentation with Melanoma Progression During Pembrolizumab Treatment.
    Nardin C; Pelletier F; Puzenat E; Aubin F
    Acta Derm Venereol; 2019 Sep; 99(10):913-914. PubMed ID: 31017249
    [No Abstract]   [Full Text] [Related]  

  • 14. Low-dose pembrolizumab induced remission in patients with refractory classical Hodgkin lymphoma.
    Kwong YL; Lopes D; Khong PL
    Br J Haematol; 2017 Jan; 176(1):131-132. PubMed ID: 26773814
    [No Abstract]   [Full Text] [Related]  

  • 15. Vasculitic neuropathy induced by pembrolizumab.
    Aya F; Ruiz-Esquide V; Viladot M; Font C; Prieto-González S; Prat A; Arance A
    Ann Oncol; 2017 Feb; 28(2):433-434. PubMed ID: 27864214
    [No Abstract]   [Full Text] [Related]  

  • 16. Coincident Metastatic Melanoma and Merkel Cell Carcinoma with Complete Remission on Treatment with Pembrolizumab.
    Thiem A; Kneitz H; Schummer P; Herz S; Schrama D; Houben R; Goebeler M; Schilling B; Gesierich A
    Acta Derm Venereol; 2017 Nov; 97(10):1252-1254. PubMed ID: 28761962
    [No Abstract]   [Full Text] [Related]  

  • 17. Locally advanced head and neck squamous cell carcinoma and melanoma simultaneously treated with pembrolizumab: an unusual situation.
    Mora-Fernández V; Boada A; Manzano JL; Jaka A; Ferrándiz C
    Eur J Dermatol; 2020 Dec; 30(6):743-744. PubMed ID: 33237032
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful treatment of unresectable recurrent programmed death ligand 1 moderately-expressing malignant melanoma of the nasal cavity with pembrolizumab monotherapy.
    Fujimura T; Kambayashi Y; Sato Y; Tanita K; Tono H; Lyu C; Takahashi T; Hashimoto A; Aiba S
    J Dermatol; 2019 Jul; 46(7):e260. PubMed ID: 30672615
    [No Abstract]   [Full Text] [Related]  

  • 19. Persistence of superficial basal cell carcinoma during pembrolizumab treatment for metastatic melanoma.
    Russo I; Filoni A; Alaibac M
    Eur J Dermatol; 2021 Feb; 31(1):99-100. PubMed ID: 33586650
    [No Abstract]   [Full Text] [Related]  

  • 20. Response to Pembrolizumab in a Patient with Relapsing Thymoma.
    Zander T; Aebi S; Rast AC; Zander A; Winterhalder R; Brand C; Diebold J; Gautschi O
    J Thorac Oncol; 2016 Dec; 11(12):e147-e149. PubMed ID: 27498287
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.